Literature DB >> 22398719

Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case.

Takafumi Watanabe1, Takaki Yoshikawa, Yoichi Kameda, Toru Aoyama, Tsutomu Hayashi, Takashi Ogata, Haruhiko Cho, Akira Tsuburaya, Satoshi Morita, Yumi Miyashita, Junichi Sakamoto.   

Abstract

We report a case of advanced gastric carcinoma treated successfully by four courses of neoadjuvant chemotherapy (NAC) with paclitaxel and cisplatin. The patient was a 43-year-old man with advanced gastric cancer, clinically diagnosed as P0H0M0CY0T3N2, which had invaded the upper body of the stomach and esophagus. He was entered into a clinical trial and received the following NAC regimen: paclitaxel 80 mg/m(2), and cisplatin 25 mg/m(2), on days 1, 8, and 15, followed by a rest on day 22, as one course. The lymph nodes had reduced in size to 59% after two courses and to 40% after four courses, with no sign of severe toxicity. Subsequently, he underwent D2 total gastrectomy with pancreatico-splenectomy. On microscopic examinations, no tumor cells were detected in the ulcer scar of the resected stomach or the regional lymph nodes. Thus, we discuss the potential of long-term NAC, especially for responders to two initial courses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398719     DOI: 10.1007/s00595-012-0155-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  19 in total

1.  Principles of surgical treatment for curable gastric cancer.

Authors:  Mitsuru Sasako
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

2.  A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study).

Authors:  T Yoshikawa; K Omura; O Kobayashi; A Nashimoto; A Takabayashi; T Yamada; H Yamaue; M Fujii; T Yamaguchi; T Nakajima
Journal:  Eur J Surg Oncol       Date:  2010-06       Impact factor: 4.424

Review 3.  Recent advances in chemotherapy for advanced gastric cancer in Japan.

Authors:  Masashi Fujii; Mitsugu Kochi; Tadatoshi Takayama
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

4.  Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination.

Authors:  Seiji Satoh; Suguru Hasegawa; Nobuhiro Ozaki; Hiroshi Okabe; Go Watanabe; Satoshi Nagayama; Masanori Fukushima; Arimichi Takabayashi; Yoshiharu Sakai
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

5.  [A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks].

Authors:  Katsunobu Sakurai; Yoshito Yamashita; Sadatoshi Shimizu; Kayo Yoshida; Tatsunari Fukuoka; Zhang Xiang; Satoshi Yamamoto; Atsushi Yamamoto; Akishige Kanazawa; Masashi Takemura; Tadashi Tsukamoto; Yukio Nishiguchi; Teruyuki Ikehara
Journal:  Gan To Kagaku Ryoho       Date:  2010-02

6.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

7.  Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.

Authors:  Hideo Baba; Manabu Yamamoto; Kazuya Endo; Yasuharu Ikeda; Yasushi Toh; Shunji Kohnoe; Takeshi Okamura
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

8.  Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer.

Authors:  Alvaro Díaz de Liaño; Concepción Yarnoz; Rubén Aguilar; Cristina Artieda; Héctor Ortiz
Journal:  Gastric Cancer       Date:  2008-07-02       Impact factor: 7.370

9.  Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer.

Authors:  Naoki Nagata; Masayuki Kimura; Naoki Hirabayashi; Akira Tuburaya; Teruo Murata; Ken Kondo; Yasuhiko Fukuda; Michiya Kobayashi; Yumi Miyashita; Akimasa Nakao; Junichi Sakamoto
Journal:  Hepatogastroenterology       Date:  2008 Sep-Oct

10.  Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.

Authors:  T Yoshikawa; M Sasako; S Yamamoto; T Sano; H Imamura; K Fujitani; H Oshita; S Ito; Y Kawashima; N Fukushima
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

View more
  4 in total

Review 1.  Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy.

Authors:  Takaki Yoshikawa; Yasushi Rino; Norio Yukawa; Takashi Oshima; Akira Tsuburaya; Munetaka Masuda
Journal:  Surg Today       Date:  2013-03-19       Impact factor: 2.549

2.  Regional Arterial Infusion Chemotherapy improves the Pathological Response rate for advanced gastric cancer with Short-term Neoadjuvant Chemotherapy.

Authors:  Zhen-Feng Wu; Qin-Hong Cao; Xiao-Yu Wu; Che Chen; Zhe Xu; Wei-Su Li; Xue-Quan Yao; Fu-Kun Liu
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

3.  The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.

Authors:  Nathan J Curtis; Fergus Noble; Ian S Bailey; Jamie J Kelly; James P Byrne; Timothy J Underwood
Journal:  J Surg Oncol       Date:  2013-11-14       Impact factor: 3.454

4.  Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection.

Authors:  Tongbo Wang; Nianchang Wang; Hong Zhou; Aiping Zhou; Jing Jin; Yingtai Chen; Dongbing Zhao
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.